EVO

Business Context and Reporting Period

Company: Evotec SE (Evotec AG)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: First Quarter ended March 31, 2009
Filing Date: May 12, 2009
Business Overview: Evotec is a biopharmaceutical company focused on the discovery and development of small molecule drugs. The company operates a Discovery Alliances Business (DAB) and maintains a proprietary pipeline. The reporting period includes the full impact of the Renovis, Inc. acquisition (completed May 2008), making year-over-year comparisons partially non-comparable.

Key Financial Metrics

Debt & Capital Structure: Total stockholders' equity was EUR 135.9 million (equity ratio 77.5%). Long-term loans totaled EUR 7.97 million. The company holds auction rate securities (ARS) valued at EUR 9.5 million, currently trading at a discount.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 13% to EUR 8.2 million, driven by the Discovery Alliances Business, higher license income, and partial recognition of a Roche upfront payment.
• Operating Loss Expansion: Reported operating loss increased 41% to EUR 20.2 million. This was primarily due to a EUR 6.6 million impairment charge related to the VR1 program and EUR 1.4 million in restructuring expenses.
• Adjusted Performance: Excluding impairment and restructuring, the operating loss improved by 15% to EUR 12.2 million, reflecting higher gross profit and reduced R&D expenses.
• R&D Expenses: Decreased 19% to EUR 10.3 million, aided by the absence of a EUR 3 million milestone payment to Roche recorded in the prior year.
• SG&A Expenses: Increased 43% to EUR 4.8 million, largely due to the inclusion of Renovis expenses and the reversal of provisions in the prior year.
• Non-Operating Items: Net loss was impacted by a EUR 1.6 million foreign exchange loss (reclassification of equity) and a EUR 0.6 million valuation loss on ARS put options.

Guidance, Outlook, and Material Events

Restructuring ("Evotec 2012")

Management implemented a cost-reduction plan to extend cash reach beyond 2012. Measures include:

• Reduction of administrative headcount by 20% and clinical development headcount by 50%.
• Re-engineering of drug discovery operations, moving proprietary programs to Europe and winding down US operations in South San Francisco.
• Expected annual cost savings of at least EUR 10 million starting in 2010 and a 30% reduction in annual cash burn.

Clinical Pipeline Updates

• Failures/Delays: EVT 302 (smoking cessation) failed Phase II proof-of-concept. EVT 201 (insomnia) missed partnering goals. The VR1 program (pain) was delayed by partner Pfizer, triggering the EUR 6.6 million impairment.
• Progress: EVT 401 (P2X7 antagonist for rheumatoid arthritis) is progressing as planned with Phase I results expected mid-2009.

Strategic Partnerships & Acquisitions

• Roche Partnership: Signed a deal with potential value exceeding $300 million for the EVT 100 compound family. Roche paid a $10 million upfront payment in April 2009 (not included in Q1 liquidity) and will fund Phase II studies for EVT 101 (treatment-resistant depression).
• Acquisition: Announced acquisition of zebrafish screening operations from Summit Corporation for £0.5 million to strengthen discovery capabilities.

Outlook & Guidance

Evotec confirmed its 2009 financial targets:

• Revenue: Expected to exceed EUR 35 million (excluding out-licensing income).
• R&D Spend: Expected to be below EUR 30 million.
• Liquidity: Year-end 2009 liquidity expected to exceed EUR 65 million, sufficient to fund operations for more than three years.

Risks

Key risks include the inability to reduce cash burn via restructuring, clinical trial failures, regulatory hurdles, and the illiquidity of auction rate securities. The failure of EVT 302 and delay of VR1 reduce the portfolio's partnering potential.

Investor Verification Checklist

• Cash Runway: Verify the impact of the EUR 10 million annual cost savings and the 30% cash burn reduction on the projected "beyond 2012" cash reach.
• Roche Deal Recognition: Confirm the revenue recognition schedule for the $10 million upfront payment and the conditions for the $65 million buyback option.
• Impairment Validity: Review the discounted cash flow assumptions used for the EUR 6.6 million VR1 impairment charge.
• Auction Rate Securities (ARS): Assess the liquidity risk and fair value discount (approx. 12.1%) on the EUR 9.5 million ARS holding.
• Restructuring Execution: Monitor the timeline for the wind-down of US operations and the realization of headcount reductions.